← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Cloudbreak Therapeutics, Llc
Irvine, CA
$3,637,195
Total funding
1
Grants
Funding over time
peak $1.5M · FY2018–21$2M$1.5M$1M$500K$0
'18
'19
'20
'21
Funding mix
By agency
NIH$3,637,195 · 1
By mechanism
R44$3,637,195 · 1
Investigators at Cloudbreak Therapeutics, Llc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
A Phase 2a Multicenter, Randomized, Vehicle-Controlled, Dose Escalating Study to Evaluate the Safety, Efficacy and Pharmacokinetics of CBT-001 Ophthalmic Solution in Pterygium Patients$809,052
R44 · FY2019 · EY
A Phase 2a Multicenter, Randomized, Vehicle-Controlled, Dose Escalating Study to Evaluate the Safety, Efficacy and Pharmacokinetics of CBT-001 Ophthalmic Solution in Pterygium Patients$739,062
R44 · FY2019 · EY
A Phase 3 Multicenter, Randomized, Vehicle-Controlled Clinical Study to Evaluate the Safety and Efficacy of an Ophthalmic Emulsion of Nintedanib in Pterygium Patients$699,988
R44 · FY2020 · EY
A Phase 3 Multicenter, Randomized, Vehicle-Controlled Clinical Study to Evaluate the Safety and Efficacy of an Ophthalmic Emulsion of Nintedanib in Pterygium Patients$677,628
R44 · FY2021 · EY
A Phase 2a Multicenter, Randomized, Vehicle-Controlled, Dose Escalating Study to Evaluate the Safety, Efficacy and Pharmacokinetics of CBT-001 Ophthalmic Solution in Pterygium Patients$384,505
R44 · FY2018 · EY
A Phase 2a Multicenter, Randomized, Vehicle-Controlled, Dose Escalating Study to Evaluate the Safety, Efficacy and Pharmacokinetics of CBT-001 Ophthalmic Solution in Pterygium Patients$326,960
R44 · FY2018 · EY